HUMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Humacyte Inc. (HUMA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The recent funding from the FY2026 DoD Appropriations Act for its bioengineered blood vessels is a strong positive catalyst, and the stock is currently trading at a low price of $1.01 in pre-market, which could present an attractive entry point for long-term growth potential.
The MACD is positive but contracting, RSI is neutral at 48.136, and moving averages are converging, indicating no strong trend. Key support is at $0.903, and resistance is at $1.216. The stock is trading near its support level, which could offer a favorable entry point.
The FY2026 DoD Appropriations Act funding for Humacyte's bioengineered blood vessels is a major positive catalyst, as it supports the company's innovation and potential for future growth. Additionally, the stock's historical pattern suggests a 6.98% potential gain in the next month.
The company's financial performance in Q3 2025 shows a significant decline in net income (-55.33% YoY) and EPS (-66.67% YoY), which may raise concerns about profitability. Retail sentiment remains bearish despite recent positive news.
In Q3 2025, revenue remained flat at $753,000 YoY, while net income dropped significantly to -$17.51 million (-55.33% YoY), and EPS fell to -$0.11 (-66.67% YoY). Gross margin improved slightly to 65.47%.
Benchmark maintains a Buy rating on HUMA but lowered the price target from $11 to $10, reflecting updated financial models. This indicates continued confidence in the stock's long-term potential despite recent financing activities.
